NovaBay Pharmaceuticals Inc (NBY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has a cash flow conversion efficiency ratio of 0.100x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.27 Million) by net assets ($-22.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NovaBay Pharmaceuticals Inc (NBY) total market value for the company's overall valuation and market capitalisation.
NovaBay Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how NovaBay Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NovaBay Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore NBY cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pelat Timah Nusantara Tbk
JK:NIKL
|
0.015x |
|
FiEE, Inc.
NASDAQ:FIEE
|
0.002x |
|
Modi Rubber Limited
NSE:MODIRUBBER
|
0.002x |
|
Yuhwa Securities Co Ltd
KO:003465
|
0.183x |
|
Raval ACS Ltd
TA:RVL
|
0.042x |
|
American West Metals Ltd
AU:AW1
|
1.581x |
|
Vitreous Glass Inc
V:VCI
|
0.226x |
|
Mishorim Real Estate Investments
TA:MSHR
|
0.014x |
Annual Cash Flow Conversion Efficiency for NovaBay Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of NovaBay Pharmaceuticals Inc from 2005 to 2025. View NovaBay Pharmaceuticals Inc (NBY) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-22.83 Million | $-8.43 Million | 0.369x | -99.08% |
| 2024-12-31 | $-129.00K | $-5.18 Million | 40.178x | +3224.87% |
| 2023-12-31 | $3.31 Million | $-4.26 Million | -1.286x | -103.94% |
| 2022-12-31 | $10.55 Million | $-6.65 Million | -0.630x | +30.24% |
| 2021-12-31 | $10.17 Million | $-9.19 Million | -0.904x | -135.80% |
| 2020-12-31 | $12.32 Million | $-4.72 Million | -0.383x | +95.30% |
| 2019-12-31 | $973.00K | $-7.93 Million | -8.149x | -625.04% |
| 2018-12-31 | $4.95 Million | $-5.57 Million | -1.124x | +53.50% |
| 2017-12-31 | $2.59 Million | $-6.27 Million | -2.417x | -41.44% |
| 2016-12-31 | $7.10 Million | $-12.13 Million | -1.709x | -146.94% |
| 2015-12-31 | $-5.10 Million | $-18.56 Million | 3.640x | +144.69% |
| 2014-12-31 | $1.85 Million | $-15.05 Million | -8.147x | -434.94% |
| 2013-12-31 | $8.52 Million | $-12.97 Million | -1.523x | -227.75% |
| 2012-12-31 | $14.05 Million | $-6.53 Million | -0.465x | -38.19% |
| 2011-12-31 | $9.34 Million | $-3.14 Million | -0.336x | -273.93% |
| 2010-12-31 | $10.49 Million | $2.03 Million | 0.193x | +256.55% |
| 2009-12-31 | $13.35 Million | $-1.65 Million | -0.123x | +90.88% |
| 2008-12-31 | $7.34 Million | $-9.94 Million | -1.354x | -209.09% |
| 2007-12-31 | $14.32 Million | $-6.27 Million | -0.438x | -116.74% |
| 2006-12-31 | $1.81 Million | $4.74 Million | 2.617x | +363.45% |
| 2005-12-31 | $3.25 Million | $-3.23 Million | -0.993x | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more